Daconib 45 Tablets β Dacomitinib 45 mg (30 Tabs) Everest
Daconib 45 mg (Dacomitinib) is a potent, second-generation targeted therapy and a generic equivalent to Vizimpro. It functions as an irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor (TKI). Unlike first-generation drugs, it binds permanently to the EGFR protein to block cancer cell growth signals.
Manufacturer: Everest Pharmaceuticals (Bangladesh). This medication represents a significant advancement in the treatment of specific types of lung cancer.
Key Features:
- β Irreversible Inhibition: Forms a permanent bond with the kinase domain of EGFR, providing sustained suppression of tumor growth.
- β First-Line Therapy: Proven to improve progression-free survival in patients with specific genetic mutations.
- β Oral Formulation: Convenient once-daily tablet administration at home.
Prescribed by oncologists for the first-line treatment of adult patients with:
- πΉ Non-Small Cell Lung Cancer (NSCLC): Metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an approved test.
Sales Unit: Bottle containing 30 film-coated tablets (45 mg strength).
β οΈ APPLICATION INSTRUCTIONS:
- Standard Dosage: 45 mg (one tablet) taken orally once daily.
- Administration: Swallow tablets whole with water at approximately the same time each day. Can be taken with or without food. Do not chew, crush, or split.
- Duration: Treatment typically continues until disease progression or unacceptable toxicity occurs.
- β Missed Dose: Take as soon as remembered. If less than 12 hours remain before the next scheduled dose, skip the missed dose. Do not take a double dose to make up for a missed one.
- β Pregnancy & Breastfeeding: Strictly contraindicated. Can cause fetal harm. Effective contraception is mandatory during treatment.
- Pediatric patients (safety and efficacy not established).
- Hypersensitivity to Dacomitinib.
- Severe hepatic or renal impairment requires caution and monitoring.
Side effects are common but manageable. Monitoring is essential:
- β οΈ Skin Reactions: Rash, dry skin, paronychia (nail infection), and pruritus are very common.
- π€’ Gastrointestinal: Diarrhea (frequent), stomatitis (mouth sores), decreased appetite, nausea.
- π« Respiratory: Interstitial Lung Disease (ILD) is a rare but serious risk. Report new or worsening cough/shortness of breath immediately.
- π Ocular: Conjunctivitis, dry eyes.
What Customers Say
No reviews yet
Your review can be the first!